American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (898)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (3939)
  2. Journal Article (1239)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (43)
  2. 2024 (217)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4951)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5323)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance])
    Meeting Abstract

    Stone, R. M.; Mandrekar, S.; Sanford, B. L.; Geyer, S.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo-Coco, F.; Klisovic, R. B.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Integrated DNA/RNA profiling for somatic alterations in adult B-cell ALL
    Meeting Abstract

    Rapaport, F.; Patel, J.; He, J.; Brennan, T. A.; Nahas, M.; Balassubramanian, S.; Otto, G.; Lipson, D.; Stephens, P.; Miller, V. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Multi-center US intergroup study of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positive acute lymphoblastic leukemia younger than 60
    Meeting Abstract

    Ravandi, F.; Othus, M.; O'Brien, S.; Forman, S. J.; Ha, C. S.; Wong, J. Y. C.; Tallman, M. S.; Paietta, E.; Racevskis, J.; Uy, G. L.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Integrative genome-wide analysis of RNA binding and splicing reveals complex loss and gain of function alterations by SRSF2 P95 mutations in myelodysplasia
    Meeting Abstract

    Rejeski, K.; Liang, Y.; Tebaldi, T.; Stefani, G.; Taylor, A.; Maziarz, J.; Song, Y. B.; Balasubramanian, K.; Vasic, R.; Kapetanovic, E.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multi-organ dysfunction: Final results from a pivotal, historically controlled, phase 3 trial
    Meeting Abstract

    Richardson, P. G.; Riches, M.; Kernan, N. A.; Brochstein, J. A.; Mineishi, S.; Termuhlen, A. M.; Arai, S.; Grupp, S. A.; Guinan, E. C.; Martin, P. L.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Targeting the Hsp90 oncoproteome in Burkitt lymphoma
    Meeting Abstract

    Roth, L. G.; van Besien, H.; Rodina, A.; Taldone, T.; Erdjument-Bromage, H.; Barth, M. J.; Chiosis, G.; Cesarman, E.
    Blood (2015)

    Fulltext@MSK | Save
  • AMC-085: A pilot trial of AVD and brentuximab vedotin in the upfront treatment of stage II-IV HIV-associated Hodgkin lymphoma. A trial of the AIDS malignancy consortium
    Meeting Abstract

    Rubinstein, P. G.; Moore, P.; Henry, D. H.; Ratner, L.; Sharon, E.; Noy, A.
    Blood (2015)

    Fulltext@MSK | Save
  • Clincial and genetic landscapes differ between IGH-CRLF2 and P2RY8-CRLF2 acute lymphoblastic leukaemia
    Meeting Abstract

    Russell, L. J.; Jones, L.; Enshaei, A.; Rutherford, J.; Tonin, S.; Ryan, S.; Eswaran, J.; Papaemmanuil, E.; Tubio, J.; Campbell, P. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) with the T315I mutation
    Meeting Abstract

    Nicolini, F. E.; Basak, G. W.; Kim, D. W.; Olavarria, E.; Pinilla-Ibarz, J.; Apperley, J. F.; Hughes, T. P.; Niederwieser, D.; Mauro, M. J.; Chuah, C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy
    Meeting Abstract

    Ottmann, O. G.; Alimena, G.; DeAngelo, D. J.; Goh, Y. T.; Heinrich, M. C.; Hochhaus, A.; Hughes, T. P.; Mahon, F. X.; Mauro, M. J.; Minami, H.; more...
    Blood (2015)

    Fulltext@MSK | Save